QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
NCT07049185
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
35
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG:
QL1706 Plus Celecoxib Group
Sponsor
Peking University Cancer Hospital & Institute